Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To explore the effectiveness and safety of tocilizumab (TCZ) with or without methotrexate
(MTX) in active rheumatoid arthritis (RA) patients showing inadequate responses to
DMARDs and/or TNF inhibitors in clinical practice.